HLA B7 anticorps (PE)

N° du produit ABIN1111104

Cet anticorps anti-HLA B7 est un anticorps Souris Monoclonal détectant HLA B7 dans FACS. Adapté pour Humain et Non-Human Primate. Ce Primary Antibody a été cité dans 6+ publications.

Aperçu rapide pour HLA B7 anticorps (PE) (ABIN1111104)

Antigène: HLA B7 (HLA Class I B7 Alpha (HLA B7))

Reactivité: Humain, Non-Human Primate

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp HLA B7 est conjugé à/à la PE

Application: Flow Cytometry (FACS)

Clone: BB7-1

Détail du produit anti-HLA B7 anticorps (PE)

Fonction: Anti-HLA-B7 PE

Specificité: The mouse monoclonal antibody BB7.1 recognizes an extracellular antigen of HLA-B7 antigen. Although highly specific, it can cross-react with HLA-B42 antigen.

Réactivité croisée (Details): Human, Non-Human Primates

Purification: Purified antibody is conjugated with R-phycoerythrin (PE) under optimum conditions. Unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.

Immunogène: Papain solubilised HLA-A2, B7

Isotype: IgG1

Information d'application

Indications d'application: Flow cytometry: The reagent is designed for analysis of human blood cells using 10 μL reagent / 100 μL of whole blood or 10⁶ cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.

Restrictions: For Research Use only

Stockage

Reconstitution: No reconstitution is necessary.

Buffer: Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Do not freeze.
Avoid prolonged exposure to light.

Stock: 4 °C

Stockage commentaire: Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.

Références pour anticorps anti-HLA B7 (PE) (ABIN1111104)

Cortez-Gonzalez, Sidney, Adotevi, Sette, Millard, Lemonnier, Langlade-Demoyen, Zanetti: "Immunogenic HLA-B7-restricted peptides of hTRT." dans: International immunology, Vol. 18, Issue 12, pp. 1707-18, (2006) (PubMed).

Hofmann, Glückmann, Kausche, Schmidt, Corvey, Lichtenfels, Huber, Albrecht, Karas, Herr: "Rapid and sensitive identification of major histocompatibility complex class I-associated tumor peptides by Nano-LC MALDI MS/MS." dans: Molecular & cellular proteomics : MCP, Vol. 4, Issue 12, pp. 1888-97, (2005) (PubMed).

de la Salle, Saulquin, Mansour, Klayme, Fricker, Zimmer, Cazenave, Hanau, Bonneville, Houssaint, Lefranc, Naman: "Asymptomatic deficiency in the peptide transporter associated to antigen processing (TAP)." dans: Clinical and experimental immunology, Vol. 128, Issue 3, pp. 525-31, (2002) (PubMed).

Rini, Selk, Vogelzang: "Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions." dans: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 5, Issue 10, pp. 2766-72, (1999) (PubMed).

Trapani, Vaughan, Tait, McKenzie: "Immunoradiometric assay for the rapid detection of HLA-B27." dans: Immunology and cell biology, Vol. 66 ( Pt 3), pp. 215-9, (1991) (PubMed).

Storkus, Alexander, Payne, Dawson, Cresswell: "Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes." dans: Proceedings of the National Academy of Sciences of the United States of America, Vol. 86, Issue 7, pp. 2361-4, (1989) (PubMed).

Détails sur HLA B7

Antigène: HLA B7 (HLA Class I B7 Alpha (HLA B7))

Autre désignation: HLA-B7

Sujet: HLA-B7 allele of human HLA class I major histocompatibility (MHC) antigen indicates higher risk of breast cancer and cervical cancer. Expression of HLA-B7 together with HLA-B27 is associated with increased susceptibility to spondyloarthropaties. Flow cytometry detection of these two alleles is being used to screen for patients, who suffer from inflammatory disorders affecting the sacroiliac and intervertebral joints, such as ankylosing spondylosis (AS). The HLA-B7 antigen (11 alleles) is expressed in 22 % of healthy Caucasian individuals.

Pathways: Human Leukocyte Antigen (HLA) in Adaptive Immune Response